Company: PACB
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001299130-25-000168
Chunk: 7

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 7
---
,989 19,718 Loss before income taxes(37,617)(60,725)(505,889)(312,222)Income tax provision383 — 116 — Net loss(38,000)(60,725)(506,005)(312,222)Other comprehensive income:Unrealized gain (loss) on investments 148 2,076 (7)1,334 Comprehensive loss$(37,852)$(58,649)$(506,012)$(310,888)Net loss per share:Basic $(0.13)$(0.22)$(1.69)$(1.15)Diluted $(0.13)$(0.22)$(1.69)$(1.15)Weighted average shares outstanding used in calculating net loss per share:Basic 300,844272,915299,303271,631Diluted 300,844272,915299,303271,631

See accompanying notes to the condensed consolidated financial statements. 

Q3 Fiscal 2025 Form 10-Q4

Table of Contents

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(Unaudited)

Three Months Ended September 30, 2025Common StockAdditional Paid-inCapitalAccumulatedOtherComprehensive IncomeAccumulated DeficitTotalStockholders'Equity(In thousands)SharesAmountBalance at June 30, 2025300,350$300 $2,677,853 $267 $(2,616,931)$61,489 Net loss—— — — (38,000)(38,000)Other comprehensive income—— — 148 — 148 Issuance of common stock in conjunction with equity plans1,5032 1,467 — — 1,469 Share-based compensation expense—— 10,984 — — 10,984 Balance at September 30, 2025301,853$302 $2,690,304 $415 $(2,654,931)$36,090 

Nine Months Ended September 30, 2025Common StockAdditional Paid-inCapitalAccumulatedOtherComprehensiveIncomeAccumulated DeficitTotalStockholders'Equity(In thousands)SharesAmountBalance at December 31, 2024294,418$294 $2,654,804